Compare Citius Pharmaceuticals Inc (CTXR) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vale SA — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Vale SA trades at $14.57 (market cap $60.78B). The key difference: Vale SA is far larger — about 4151.6× Citius Pharmaceuticals Inc's market cap, and Vale SA pays a 8.63% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | VALE | |
|---|---|---|
Market Cap | $14.64M | $60.78B |
Sector | Health | Basic Materials |
52-Week High | $1.82 | $17.82 |
52-Week Low | $0.53 | $9.53 |
Enterprise Value | $10.86M | $77.70B |
Dividend Yield | — | 8.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
VALE trades at $14.18, down 1.94% for the day, amid a bearish technical signal and mixed earnings history. The company reported revenue of $38.40B in 2025 with a net income margin of 7.21%, while recent news highlights a $2.6B decarbonization investment and governance developments. Cash flow remains positive, with operating cash flow at $8.80B in 2025.
The outlook is cautious; while analyst consensus is a Buy with a $17.50 price target, fundamental pressures from declining profit margins and a high debt-to-asset ratio of 24.66% pose risks. Upside depends on commodity price stability and execution of strategic investments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
